Category: Legislation
As the European cannabis conference season gets started, industry experts, lawmakers, regulators and business owners are facing greater mainstream scrutiny than ever before. From police raids in Portugal and North Macedonia, to a media backlash in the UK, operators are facing increasing questions about the industry’s resilience in the face of coordinated pushback. Europe’s largest […]
More than 70 international speakers and over 1000 delegates set to convene on London next month for policy debates, high-level networking and the 2026 Business of Cannabis Awards Cannabis Europa, the leading B2B conference for the European cannabis industry, today announced the full programme for its 2026 London edition. Taking place at The Barbican on […]
As the European medical cannabis market has developed, expanded and matured over the last half-decade, Portugal has played a critical role in the global supply chain, earning a reputation as the ‘doorway to Europe’. Dried flower from Canada, Colombia, Thailand and a swathe of other global exporters has been diverted through the Portuguese processing hub […]
Germany’s imports for 2025 surpassed 200 tonnes for the first time, exceeding the country’s already revised import quota for the second time in a year. The latest medical cannabis import figures from BfArM, covering the final quarter of 2025, show that the post-CanG boom may finally be slowing after consecutive periods of high double-digit growth. […]
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m. Given its size, especially compared to the relatively modest acquisition of Remexian late last year, it’s no surprise Sanity’s deal has captured the market’s […]
As Europe’s medical cannabis markets continue to mature, an increasingly familiar pattern is beginning to emerge. First, access opens and demand surges. Then operators and products flood into the market, leading to the compression of both the price for patients and the margins for businesses. This, inevitably, is followed by consolidation as those without the […]
Since the emergence of the legal cannabis industry across the Western world, operators have persistently been forced to deal with an issue faced by few counterparts in established sectors: they can’t get insured. In the UK, we’ve reported on firms seeing their bank accounts closed overnight with no explanation, facing rejections for even basic employer […]
Why are Europe’s emerging markets excluding flower? Martinez argues that the shift away from flower is a natural evolution in a market focused purely on cannabis as a medicine, helping grease the wheels of integration into existing healthcare models. “Both France and Spain have launched highly restrictive, hospital-oriented programmes,” he explained. “In that setting, excluding […]
Extracts over flower Another key part of the pharmaceutical focus is the omission of raw cannabis flower, a controversial choice for many, but one that is becoming increasingly common in emerging markets such as Spain’s incoming framework. While flower is technically permitted, it is heavily restricted to sealed, single-use vape cartridges for use with CE-approved […]
The Legal Arguments Both appeals challenge the decree on multiple grounds, with a strong emphasis on patient access and equity rather than business interests. CEOFA’s December appeal argues the decree ‘incurs in a regulatory excess, violating the principle of normative hierarchy and directly contradicting the provisions of the Law on Guarantees and Rational Use of […]
